Revolution Medicines Inc Aktie News

It's apparently in talks to be sold to a pharmaceutical industry titan. The price being discussed reaches into the tens of billions of dollars.

Revolution is developing drugs that target a molecular driver of cancers.

Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores R...

Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy First Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLC Revo...

Shareholders in both drugmakers appear disappointed that a deal may not happen.

AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.